Core Insights - The company achieved a revenue of 25.113 billion yuan in the first half of 2025, a 14% increase year-on-year, driven by property development and Jinmao services [1] - The company’s net profit attributable to shareholders, excluding non-recurring items, reached 1.123 billion yuan, a 2% increase year-on-year, primarily due to a reduction in marketing and management expenses [1] Revenue and Profitability - The revenue from land and property development was 20.041 billion yuan, up 17% year-on-year, while Jinmao services generated 1.783 billion yuan, reflecting a 20% increase [1] - The company’s marketing and management expenses decreased by 15% and 5% respectively compared to the previous year [1] Sales Performance - The company upgraded its four major product lines, achieving total sales of 53.35 billion yuan, a 16.36% increase from 44.62 billion yuan in 2024, and improved its sales ranking to 9th nationally [1] - In January 2025, the company sold four plots of land in Huzhou for 781 million yuan, marking a successful exploration of land reserves [1] Land Acquisition and Project Development - The company acquired 16 plots of land in key cities such as Shanghai, Beijing, Hangzhou, and Chengdu, with a total planned construction area exceeding 1.45 million square meters [2] - The total new value of projects added in the first half of 2025 was 74.9 billion yuan, ranking third nationally, with equity value added at 40.3 billion yuan [2] Financing and Cost Management - The company has diversified its funding channels, issuing bonds totaling 53 billion yuan in 2025, with significantly reduced interest rates [2] - Interest expenses for the company were 3.256 billion yuan, an 8% decrease year-on-year, while capitalized interest expenses were 2.042 billion yuan, down 10% [2] Future Outlook - The company is expected to see revenues of 63.64 billion yuan, 69.44 billion yuan, and 76.79 billion yuan from 2025 to 2027, with net profits projected at 1.355 billion yuan, 1.910 billion yuan, and 2.718 billion yuan respectively [3] - The company benefits from the backing of its parent company, China National Chemical Corporation, which provides a competitive financing advantage [3]

Core Viewpoint - Zhejiang Medicine's 2024 performance met market expectations, with significant revenue and profit growth driven by rising prices of vitamins A and E [1][2] Financial Performance - In 2024, Zhejiang Medicine reported revenue of 9.375 billion yuan, a year-on-year increase of 20.3%, and a net profit of 1.161 billion yuan, corresponding to earnings per share of 1.21 yuan, up 170% year-on-year, aligning with market expectations [1] - The company's Q4 2024 revenue was 2.262 billion yuan, with year-on-year growth of 18% but a quarter-on-quarter decline of 16.4%. Net profit for Q4 was 311 million yuan, showing a year-on-year increase of 142% but a quarter-on-quarter decrease of 41.8% due to a 1.62 billion yuan asset impairment loss [1] - The nutrition segment generated revenue of 4.697 billion yuan in 2024, a year-on-year increase of 43.51%, with vitamin product sales reaching 52,688 tons, up 32.87% year-on-year [1] Market Trends - Vitamin E and A prices are experiencing a slight decline from their high levels, with current domestic vitamin E prices at 119 yuan/kg, down 23.5 yuan/kg from the beginning of the year, and vitamin A prices at 78 yuan/kg, reflecting a significant drop from the Q3 2024 peak [4] - Despite the price drop, strong production capabilities and a willingness to maintain prices among producers are expected to keep the market relatively stable [4] Strategic Developments - The company is focusing on product line upgrades and optimizing capacity layout, with successful trials of new processes in the nutrition segment and ongoing construction of new facilities for pharmaceutical products [4] - The company is optimistic about strengthening its long-term competitiveness and the gradual realization of growth in its pharmaceutical business [4] Profit Forecast and Valuation - Due to the decline in vitamin prices, the profit forecast for 2025 has been reduced by 28% to 1.09 billion yuan, with a new forecast for 2026 set at 1.1 billion yuan [5] - The target price has been adjusted down by 13% to 16.5 yuan, reflecting a price-to-earnings ratio of 14.5 for 2025 and 2026, with a potential upside of 21% [5]